Adiga Life Sciences Inc. developed a novel immunotherapeutic platform in which small components (peptides) of allergen proteins are identified and administered in a regimen that causes immune cells to become non-responsive towards the allergens. In a phase II clinical trial, the cat allergy treatment developed by Adiga using this platform reduced allergic symptoms in allergic […]
Read More